The use of itraconazole as prophylaxis against invasive fungal infection in blood and marrow transplant recipients

Transplant Infectious Disease

Volumn 2, Issue 2, 2000, Pages 72-79

  Boyle, B M ^a   McCann, S R ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Aspergillus; Blood and marrow transplant; Candida; Chemoprophylaxis; Invasive fungal infection; Itraconazole; Neutropenia

Indexed keywords

AMPHOTERICIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBAMAZEPINE; CEFTAZIDIME; CLARITHROMYCIN; CYCLODEXTRIN; CYCLOSPORIN A; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; FLUCONAZOLE; FLUDARABINE; GLYCOPEPTIDE; HYDROXYITRACONAZOLE; ISONIAZID; ITRACONAZOLE; METHYLPREDNISOLONE; MIDAZOLAM; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN; QUINIDINE; RIFAMPICIN; STEROID; TACROLIMUS; VINCA ALKALOID; VINCRISTINE;

ANTIFUNGAL ACTIVITY; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HYPOKALEMIA; INFECTION PREVENTION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITRACONAZOLE; MYCOSES; RISK FACTORS; VIRUS DISEASES;

EID: 0034022846     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020205.x     Document Type: Review

References (45)

1. DENNING DW, STEVENS DA. Antifungal and surgical treatment of invasive aspergillosus: review of 2,121 published cases. Rev Infect Dis 1990: 12: 1147-1201.
2. DENNING DW, STEPAN DE, BLUME KG, et al. Control of invasive pulmonary aspergillosis with oral itraconazole in bone marrow transplant patients. J Infect 1992: 24: 73-79.
3. ANAISSIE E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992: 14 (Suppl 1): S43-S54.
4. AVERSA F, TABILIO A, VELARDI A. Treatment of high risk acute leukaemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998: 339: 1186-1193.
5. WINGARD JR. Importance of candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995: 20: 115-125.
6. WINGARD JR, MERZ WG, RINALDI MG. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991: 325: 1274-1277.
7. WINGARD JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Inf Dis 1994: 19 (Suppl): S49-S53.
8. WORKING PARTY OF THE BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY. Therapy of deep fungal infection in haematological malignancy. Antimicrob Chemother 1997: 40. 779-788.
9. GOODMAN JL, WINSTON DJ, GREENFIELD RA, CHANDRASEKAR PH. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplant. N Engl J Med 1992: 326: 845-851.
10. EZDINLI EZ, O'SULLIVAN DD, WASSER LP, et al. Oral amphotericin for candidiasis in patients with haematologic neoplasms. JAMA 1979: 242: 258-260.
11. MEUNTER-CARPENTIER F. Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections. Am J Med 1984: 76: 652-656.
12. BUCHANAN AG, RIBEN PD, RAYNER EN, et al. Nystatin prophylaxis of fungal colonization, infection in granulocytopenic patients, correlation of colonization and clinical outcome. Clin Invest Med 1985: 8: 139-147.
13. KELSEY SM, GOLDMAN JM, MCCANN S, et al. Liposomal amphotericin in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999: 23: 163-168.
14. PHILPOTT-HOWARD JN, WADE JJ, MUFTI GJ, et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Mulncenter Study Group. J Antimicrob Chemother 1993: 31. 973-984.
15. SLAVIN MA, OSBORNE B, ADAMS R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomised, double-blind study. J Infect Dis 1995: 171: 1545-1552.
16. WINSTON DJ, CHANDRASCKAR PH, LAZARUS HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukaemia. Results of a randomised placebo-controlled, double-blind, multicentre trial. Ann Intern Med 1993: 117: 495-503.
17. ELLIS ME, CLINK H, ERNST P. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994: 13: 3-11.
18. BRINCKER H, et al. Prophylactic treatment with miconazole inpatients highly predisposed to fungal infections. A placebo-controlled, double-blind study. Acta Med Scand 1978: 264: 123-128.
19. MICHAUX JL, JACQUEMIN P, CORNA G, et al. Use of miconazole for prevention of opportunistic fungal infection during treatment of haematological malignancy. Proc R Soc Med 1977: 70 (Suppl 1): 32-34.
20. PRENTICE HG, CAILLOT D, DUPONT B, et al. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: meeting report. Acta Haematol Nov 1999: 101: 56-62.
21. BOOGAERTS MA. Risks involved in selective decontamination in immunocompromised patients. Mycoses 1989: 32 (Suppl 1): 103-108.
22. STEVENS DAVIS A. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999: 19: 603-611.
23. VAN DE VELDE VJ, VAN PEER AP, HEYKANTS JJ, et al Effect of food on the pharmacokinetics of a new hydroxpropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996: 16: 424-428.
24. REEVES DS, WISE R, ANDREWS M, WHITE L. Clinical Antimicrobial Assays. London: Oxford University Press, 1999.
25. MASCHMEYER G. Use of quinolones for the prophylaxis and therapy of infections in immunocompromised hosts. Drugs 1993: 45 (Suppl 3): 73-80. Review.
26. BRADLEY S, WILSON A, ALLEN MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus species on a haematology unit by changing antibiotics usuage. J Antimicrob Chemother 1999: 43: 261-266.
27. HOBAN DJ, ZHANEL GG, KARLOWSKY JA, et al. In vitro susceptibility of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrobial Agents Chemther 1999: 43: 1463-1464.
28. DANNAOUI E, PERSAT F, MONIER M-F, PICOT S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin and itraconazole. J Antimicrob Chemother 1999: 44: 553-557.
29. SCHAFFNER A, SCHAFFNER M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use and health care costs in patients undergoing intensive chemotherapy for haematological neoplasias. J Infect Dis 1995: 172: 1035-1041.
30. PERFECT JR, KLOTMAN MF, GILBERT CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipents. J Infect Dis 1992: 165: 891-897.
31. MENICHETTI F, DEL FAVERO A, MARTINO P. GIMEMA Infection Program: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with haematological malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999: 28: 250-255.
32. MORGENSTERN GR. Itraconazole oral solution versus fluconazole suspension for antifungal prophlaxis I neutropenic patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, 1996.
33. HAROUSSEAU JL, STAMATOULLAS A, DEKKER A, DE BOCK B, et al. Prophylaxis of fungal infections in haematological malignancies: a double-blind trial comparing itraconazole solution to amphotericin B capsules. Blood 1999: 92: 10: 3202.
34. FOOT ABM, VEYS PA, GIBSON BES. Itraconazole as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999: 24: 1089-1093.
35. GALLARDO-QUESADA S, LUELMO-AGUILAR J, GUANYABENS-CALVET C. Hepatotoxicity associated with itraconazole. Int J Dermatol 1995: 34: 589.
36. GILLES J, HUNG KA, FITZSIMONS E, et al. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998: 20: 123-124.
37. GROLL A, et al. Pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in paediatric patients with HIV infection and oropharyngeal candidiasis. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1999.
38. CORNISH J, JOHNSON E, OAKHILL A. The use of intravenous itraconazole in aspergillosis following pure UR UD BMT. Haematologica 1999: PU-1135 vol. 84 (EHA-4 Abstract book).
39. CAILLOT D, BASSARIS H, SEIFERT WF, et al. Efficacy and safety and pharmacokinetics of intravenous followed by oral itraconazole in patients with invasive aspergillosis. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICACC) 1999: 575: 1646.
40. BOOGAERTS M, GARBER G, WINSTON D, et al. Itraconazole compared with amphotericin B as empirical therapy for persistent fever of unknown origin in neutropenic patients. Bone Marrow Transplant 1999: 23 (Suppl 1): 358.
41. MICHALLET M, PERSAT F, KRANZHOFER N, et al. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplants patients receiving total body irradiation. Bone Marrow Transplant 1998: 21: 1239-1243.
42. DE PENTIGNY L, RATELLE J, LECLERC JM, et al. Repeat-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998: 42: 404-408.
43. CHEYMOL G, POIVIER JM. Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring. Bull Acad Natl Med 1999: 183: 371-380.
44. GLASMACHER A, HAHN C, MOLITOR E, SCHMIDT-WOLF IGH. Definition of a minimal effective trough concentration of itraconazole for antifungal prophylaxis in severely neutropenic patients with haematologic malignancies. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1999: 145.J: 1417.
45. DE LUCCA AJ, WALSH TJ. Antifungal peptides: novel compounds against emerging pathogen. Antimicrob Agents Chemother 1999: 43: 1-11.